Core Viewpoint - Lin Qingxuan Cosmetics Group Co., Ltd. has successfully listed on the Hong Kong Stock Exchange, closing at HKD 85.00 with a 9.30% increase on the first day of trading [1]. Group 1: IPO Details - The total number of shares offered globally was 13,966,450 H-shares, with 1,396,650 shares for public offering in Hong Kong and 12,569,800 shares for international offering [2]. - The offering price was set at HKD 77.77, raising a total of HKD 1,086.2 million, with net proceeds amounting to HKD 997.1 million after deducting estimated listing expenses of HKD 89.1 million [5]. Group 2: Use of Proceeds - The net proceeds from the global offering will be used for brand value enhancement, development of a multi-channel sales network, establishment of overseas sales channels, strengthening production and supply chain capabilities, technology research and development, and digital transformation of operations [5]. Group 3: Financial Performance - Lin Qingxuan's total revenue for 2022, 2023, 2024, and the six months ending June 30, 2025, were RMB 691.2 million, RMB 805.0 million, RMB 1,209.6 million, and RMB 1,051.8 million respectively [5][6]. - The company reported a net loss of RMB 5.9 million in 2022, followed by net profits of RMB 84.5 million in 2023 and RMB 186.8 million in 2024 [6][7]. Group 4: Cash Flow and Expenses - The net cash generated from operating activities was RMB 65.3 million in 2022, increasing to RMB 205.8 million in 2023, and projected to be RMB 306.5 million in 2024 [8]. - Sales expenses reached RMB 688.5 million in 2024, accounting for 56.86% of revenue, while R&D expenses were only RMB 30.4 million, representing 2.5% of revenue [8].

Core Viewpoint - Lin Qingxuan (02657) is positioned as a high-end skincare brand focusing on camellia oil, experiencing rapid growth in 2023, with plans for an IPO by December 30, 2025, aiming to raise approximately HKD 9.97 billion (around RMB 8.97 billion) for channel expansion and brand development [1] Group 1: Company Overview - Lin Qingxuan, established in 2003, specializes in high-end skincare with a focus on anti-aging, leveraging its proprietary camellia oil [1] - As of H1 2025, Lin Qingxuan operates 554 offline stores, primarily located in high-end shopping malls, and is projected to rank first among domestic high-end skincare brands in 2024 [1] Group 2: Market Dynamics - The Chinese cosmetics market is expected to reach approximately RMB 688.6 billion in 2024, with skincare products accounting for 67% of sales [2] - The high-end skincare segment is projected to grow at a CAGR of 13.8% from 2024 to 2029, while the facial oil segment is anticipated to grow at a CAGR of 42.8% during the same period, reaching a market size of RMB 13.9 billion by 2029 [2] Group 3: Financial Performance - For 2024, Lin Qingxuan's revenue and net profit are projected to be RMB 1.21 billion and RMB 190 million, respectively, reflecting year-on-year increases of 50% and 121% [3] - In H1 2025, the company reported revenue of RMB 1.052 billion, a 98% increase year-on-year, with net profit reaching RMB 182 million, up 110% [3] - The core product, camellia oil essence, has maintained the top sales position in the facial oil category for 11 consecutive years, with H1 2025 sales increasing by 176% [3] Group 4: IPO and Future Strategy - The IPO proceeds will focus on brand enhancement, channel development, supply chain improvements, and multi-brand strategies [4] - Key long-term strategies include brand rejuvenation targeting younger consumers, synergistic channel development, and expanding product categories beyond anti-aging to include whitening and makeup [4] - Profit forecasts for 2025-2027 indicate net profits of RMB 382 million, RMB 578 million, and RMB 742 million, with respective growth rates of 104.24%, 51.50%, and 28.38% [4]

Core Viewpoint - Lin Qingxuan is positioned as a high-end skincare brand focusing on camellia oil, experiencing rapid growth in 2023, with plans for an IPO by December 30, 2025, aiming to raise approximately HKD 9.97 billion (RMB 8.97 billion) for channel expansion and brand development [1][5] Group 1: Company Overview - Lin Qingxuan, established in 2003, specializes in high-end skincare with a focus on anti-aging, leveraging its proprietary camellia oil [2] - As of the first half of 2025, Lin Qingxuan operates 554 offline stores, primarily located in high-end shopping malls, and is projected to rank first among domestic high-end skincare brands in 2024 [2] Group 2: Market Dynamics - The Chinese cosmetics market is projected to reach approximately RMB 688.6 billion in 2024, with skincare products accounting for 67% of sales, and high-end skincare expected to grow at a CAGR of 13.8% from 2024 to 2029 [3] - The facial essence oil segment is experiencing rapid growth, with a CAGR of 42.8% from 2019 to 2024, expected to reach a market size of RMB 13.9 billion by 2029 [3] Group 3: Financial Performance - In 2024, Lin Qingxuan's revenue and net profit are projected to be RMB 1.21 billion and RMB 190 million, respectively, reflecting year-on-year increases of 50% and 121% [4] - For the first half of 2025, revenue reached RMB 1.052 billion, a 98% increase year-on-year, with net profit of RMB 182 million, up 110% [4] - The core product, camellia oil essence, has maintained the top sales position in the facial essence oil category for 11 consecutive years, with a 176% year-on-year revenue increase in the first half of 2025 [4] Group 4: IPO and Future Strategy - The IPO proceeds will focus on brand enhancement, channel development, supply chain improvements, and multi-brand strategies [5] - Key long-term strategies include brand rejuvenation targeting younger consumers, synergistic channel development, and expanding product lines into whitening and makeup categories [5] - Profit forecasts indicate net profits of RMB 382 million, RMB 578 million, and RMB 742 million for 2025 to 2027, with corresponding year-on-year growth rates of 104.24%, 51.50%, and 28.38% [5]

Investment Rating - The report recommends subscription for Lin Qingxuan (2657.HK) [1] Core Insights - The company focuses on the high-end domestic skincare market, particularly anti-wrinkle and firming products, with a comprehensive range of offerings including essential oils, creams, toners, emulsions, serums, and masks. The core product is camellia oil [2] - In 2024, the company ranks 13th among all high-end skincare brands in China and 10th in the anti-wrinkle segment, with market shares of 1.4% and 2.2% respectively [2] - The Chinese skincare market has shown steady growth, with a CAGR of 6.8% over the past six years. The market size is projected to increase from CNY 332.9 billion in 2019 to CNY 461.9 billion in 2024, with the high-end segment expected to grow from CNY 74.9 billion to CNY 114.4 billion during the same period [2] - By 2029, the overall skincare market is anticipated to reach CNY 698.5 billion, with a CAGR of 8.6% from 2024 to 2029, while the high-end segment is expected to grow to CNY 218.5 billion, with a CAGR of 13.8% [2] Financial Performance - The company has accelerated revenue growth and improved profitability, achieving revenues of CNY 0.691 billion, CNY 0.805 billion, CNY 1.210 billion, and CNY 1.052 billion for the first half of 2022 to 2025, with year-on-year growth rates of +16.5%, +50.3%, and +98.3% [3] - Net profits transitioned from a loss of CNY -0.06 billion in 2022 to CNY 0.85 billion in 2023, and further to CNY 1.87 billion and CNY 1.82 billion in 2024 and 2025, with year-on-year growth rates of +121.1% and +109.9% [3] - The gross profit margins for the same period were 78.0%, 81.2%, 82.5%, and 82.4%, while net profit margins were -0.9%, 10.5%, 15.4%, and 17.3% [3] - The company is positioned as a leading high-end domestic skincare brand, leveraging traditional Chinese botanicals to build its brand image. Future strategies include expanding product categories around core items and enhancing multi-channel operations [3] - The total market capitalization for this issuance is estimated at CNY 10.86 billion, with an initial public offering price corresponding to a static PE ratio of approximately 53.8, compared to the industry average PE of 28.3 for 2025 [3]

Core Viewpoint - Lin Qingxuan, a high-end domestic skincare brand, is facing market skepticism as it attempts a second IPO in Hong Kong after its previous prospectus expired, primarily due to its heavy reliance on a single product, Camellia Oil, which accounts for a significant portion of its revenue [2][5]. Financial Performance - Lin Qingxuan's revenue from 2022 to the first half of 2025 showed a notable increase, with figures of 6.91 billion, 8.05 billion, 12.1 billion, and 10.52 billion respectively. The net profit for the same periods was -0.5931 billion, 0.84518 billion, 1.87 billion, and 1.82 billion, with gross margins of 78%, 81.2%, 82.5%, and 82.4% [4]. Product Dependency - The company's revenue is heavily dependent on its flagship product, Camellia Oil, which generated 4.48 billion in 2024, accounting for 37% of total revenue, and further increased to 45.5% in the first half of 2025, with revenue reaching 4.79 billion. Other product lines, such as creams and lotions, have consistently contributed less than 20% to total sales [5][6]. Marketing vs. R&D Investment - Lin Qingxuan's marketing and promotional expenses have significantly outpaced its research and development (R&D) investments, with total marketing costs reaching 11.21 billion, which is 12.55 times higher than its R&D costs of 8930.1 million during the same period. The marketing expenses accounted for approximately 30% of total revenue [6][7]. Compliance Issues - The company has faced multiple penalties for false advertising, indicating systemic issues in its promotional management. Recent fines include 21,200 for misleading claims about product efficacy, contributing to a negative perception that could impact its IPO process [8][9]. Shareholder Structure - Prior to the IPO, the founder, Sun Laichun, holds 38.21% of the shares directly and approximately 79.27% in total through various entities. External investors include companies like Youngor Fashion and Country Garden Venture Capital [9][10]. Market Position - Lin Qingxuan ranks first among domestic high-end skincare brands in China based on retail sales as of 2024, with a total of 230 SKUs across various product categories [3].

Investment Rating - The report maintains a "Positive" investment rating for the industry [1] Core Insights - The report highlights the growth in tourism between China and Cambodia, driven by the new visa-free policy, which is expected to boost tourist flows [5][15] - The breakfast market in China is identified as a significant opportunity, with major brands like Mixue and Guoming entering the segment [6][33] - The education sector is experiencing a shift towards vocational training due to declining numbers in traditional higher education applications, emphasizing employment-oriented education [39][44] - Lin Qingxuan, a high-end domestic skincare brand, is showing strong growth in both online and offline sales, with a notable increase in revenue and profit margins [45][50] Summary by Sections 1. Travel and Tourism - Cambodia has implemented a visa-free policy for Chinese citizens, expected to increase tourist numbers significantly, with a 45% year-on-year increase in Chinese tourists from January to October 2025 [5][15] - In November 2025, Hainan's duty-free shopping reached 2.38 billion yuan, a 27.1% increase year-on-year, despite a slight decrease in shopping visitors [23][24] 2. Breakfast Market - The breakfast market in China is valued at approximately 1.7 trillion yuan, with the external breakfast market estimated between 700 to 800 billion yuan [6][33] - Mixue has launched breakfast offerings in several cities, targeting consumers with affordable pricing [37][38] 3. Education Sector - The number of students taking the national college entrance examination has decreased for the first time in eight years, with a significant drop in graduate school applications [39][40] - Vocational education is gaining traction as students seek better employment outcomes, with a reported 95%+ employment rate in vocational programs [44] 4. Skincare Industry - Lin Qingxuan reported a revenue of 1.05 billion yuan in the first half of 2025, marking a 98.3% year-on-year increase, with online sales growing significantly [45][47] - The brand's product mix includes a high proportion of premium skincare items, contributing to improved profit margins [50][55] 5. Market Performance - The Hong Kong stock market saw the consumer services and media sectors underperforming, while the retail sector outperformed the market [59][65] - Notable stock performances included significant gains in retail and education sectors, with specific companies like Liufu Group and Gaoxin Retail leading the gains [65][66]

Core Viewpoint - Lin Qingxuan, a high-end domestic skincare brand, is facing scrutiny as it aims for an IPO in Hong Kong, with concerns about its high pricing strategy and underlying business fundamentals [1][7] Group 1: High-End Positioning - Lin Qingxuan emphasizes its status as the only domestic brand among China's top 15 high-end skincare brands, with its camellia oil priced at 1,119 yuan for 50ml, marking its entry into the high-end market [2][9] - The company's gross margin improved from 78.0% in 2022 to 82.5% in 2024, surpassing international brands like L'Oréal and Estée Lauder [10] - However, the company's R&D investment is significantly low, totaling less than 100 million yuan from 2022 to 2024, while marketing expenses reached 760 million yuan, raising doubts about its technological capabilities [10] Group 2: Marketing-Driven Growth - The rise of Lin Qingxuan is closely linked to the founder's "internet celebrity" marketing approach, which, while generating buzz, contrasts with the brand's high-end image [3][11] - Marketing and promotional expenses from 2022 to 2024 totaled 760 million yuan, with a notable increase in 2024, raising questions about the sustainability of this growth model in a competitive market [11] Group 3: Channel Expansion Challenges - Lin Qingxuan's revenue from online channels increased from 45.2% in 2022 to 59.1% in 2024, with Douyin contributing significantly [12] - There is a stark contrast in average transaction values between online (around 500 yuan) and offline channels (around 1,000 yuan), leading to a disparity between the brand's high-end positioning and actual market prices [12] - The company faced challenges with its franchise model, leading to a high closure rate of 28.1% for franchise stores, prompting a shift back to a more controllable partnership model [13] Group 4: Regulatory Risks and Brand Narrative - Lin Qingxuan has faced penalties for false advertising, including a fine of approximately 21,200 yuan for misleading claims about its products [14] - The brand's high-end narrative is questioned due to its reliance on mass-market channels, contrasting with competitors that have established themselves in premium retail spaces [15] - The company plans to enhance its presence in first and second-tier cities while expanding into lower-tier markets, raising concerns about maintaining brand integrity [15]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Shanghai Linqingxuan Biotechnology Co., Ltd. to provide supplementary materials regarding administrative penalties for false advertising and the transfer of shares involving new shareholders as the company prepares for its overseas listing [1][12]. Financial Performance - Linqingxuan achieved revenues of 691.5 million RMB, 805 million RMB, and 1.21 billion RMB for the years 2022, 2023, and 2024 respectively, with net profits of -5.93 million RMB, 84.5 million RMB, and 186.8 million RMB during the same period [5][6]. - The company reported a significant increase in sales, with a notable rise in gross profit from 539.1 million RMB in 2022 to 997.7 million RMB in 2024 [6]. Product Dependency - The company has a growing reliance on a single product category, with sales of essence oil products accounting for 31.5%, 35.3%, and 37.0% of total sales from 2022 to 2024 [6][8]. - Linqingxuan's primary brand contributes to 99.1%, 99.0%, and 99.0% of total revenue during the same period, indicating a significant dependency on its flagship brand [8]. Marketing and R&D Expenditure - Marketing expenses have been significantly higher than R&D costs, with sales and distribution expenses amounting to 5.09 billion RMB, 4.86 billion RMB, and 6.88 billion RMB, representing 73.66%, 60.37%, and 56.86% of revenues respectively [11]. - In 2024, marketing and promotional expenses reached approximately 365 million RMB, which is 12 times the R&D expenditure of 30.4 million RMB [11]. Regulatory and Compliance Issues - Linqingxuan faced penalties for false advertising, specifically for claims regarding anti-aging effects that did not align with actual product capabilities, leading to a fine of over 21,000 RMB [12]. - The CSRC has requested clarification on the company's compliance with regulations following these penalties and the implications for its upcoming listing [12][15]. Shareholder Changes - Recently, the company welcomed a new shareholder, Youngor Fashion Technology Co., Ltd., which acquired a 4.491% stake, becoming the fourth largest shareholder [14]. - The CSRC has also requested details regarding the pricing and rationale behind recent share transfers involving new shareholders [15].

Core Viewpoint - Lin Qingxuan, a leading high-end domestic skincare brand in China, is attempting to enter the capital market with an IPO, but there are concerns about its high-end positioning and reliance on marketing expenditures [2][3][4]. Financial Overview - Lin Qingxuan's sales and distribution expenses for 2022 to 2024 are projected to be 509 million, 486 million, and 688 million RMB, respectively, accounting for 73.66%, 60.37%, and 56.86% of revenue [11]. - The company reported revenues of 691.15 million, 805.004 million, and 1.209641 billion RMB for the years 2022, 2023, and 2024, respectively [14]. Marketing and Sales Strategy - The company has heavily invested in marketing, with 1,739 out of 2,043 employees (85.2%) dedicated to sales and marketing roles [15]. - Lin Qingxuan's pricing strategy aligns with its high-end branding, with products priced at 599 RMB for 30ml of camellia oil and 730 RMB for 50g of anti-wrinkle cream [11]. Consumer Concerns - There have been numerous consumer complaints regarding product safety, including allergic reactions and misleading advertising claims [6][10]. - The brand faced regulatory scrutiny for advertising claims that did not match the actual efficacy of its products, resulting in a fine of 21,000 RMB [6]. Research and Development - Lin Qingxuan's R&D expenditures for 2022 to 2024 are 21.12 million, 19.74 million, and 30.40 million RMB, which are significantly lower compared to its marketing expenses [13]. - The R&D expense ratio is relatively low, with rates of 3.06%, 2.45%, and 2.51% for the respective years, indicating a lack of investment in foundational research compared to international competitors [13][15]. IPO and Future Outlook - The upcoming IPO could provide funding for R&D and supply chain upgrades, but there are doubts about whether the company will prioritize these areas over continued marketing expenditures [18]. - Concerns arise from the founder's pre-IPO cash-out of approximately 22 million RMB, raising questions about the long-term vision of the brand [16][18].

Core Viewpoint - Lin Qingxuan Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, focusing on the anti-wrinkle and firming skincare market with a strong emphasis on high-end skincare solutions based on natural camellia ingredients [1][2]. Financial Performance - From 2022 to 2024, Lin Qingxuan's revenue grew from 691 million RMB to 1.21 billion RMB, while the net profit attributable to the parent company improved from a loss of 5.87 million RMB to a profit of 187 million RMB [7][9]. - The gross profit margin increased from 78% to 82.5% during the same period [8]. Sales and Distribution - Sales and distribution expenses reached 688 million RMB in 2024, exceeding 50% of the total revenue [1][9]. - The revenue from offline channels decreased from 54.7% in 2022 to 40.8% in 2024, while online channel revenue increased from 45.2% to 59.1% [4][6]. Product Portfolio - As of December 31, 2024, Lin Qingxuan offered 188 SKUs, with significant revenue contributions from essence oils, creams, lotions, and masks, each accounting for over 10% of total revenue [3][4]. Market Position - In 2024, Lin Qingxuan ranked first among all high-end domestic skincare brands in China by retail sales and was the only domestic brand among the top 15 high-end skincare brands, which included both domestic and international brands [2][3]. Use of Proceeds - The funds raised from the listing will be used for brand value enhancement, deepening the multi-channel sales network, and strengthening production and supply chain capabilities [10].